Key Points:
1.The licensing program is expected to bring in an additional 6 billion rubles to the budget annually.
2.Of the total, 3 billion rubles will be specifically allocated for the treatment of COPD patients.
3.Chronic Obstructive Pulmonary Disease (COPD) has become the second leading cause of death among individuals aged 35-45.
According to the Russian media outlet Tehnowar, the Russian Democratic Forces have proposed using funds obtained from the introduction of retail licenses for nicotine products to support the fight against Chronic Obstructive Pulmonary Disease (COPD).
The assistant vice president of the association made the above remarks at the "Shemashko Russian Medical Forum."
This concept involves using funds from the introduction of retail licenses for nicotine products to support the fight against chronic obstructive pulmonary disease.
According to the organization's initial estimates, the implementation of a licensing system is expected to generate over 60 billion rubles ($7.4 billion) in revenue annually. Of this amount, 30 billion rubles ($3.7 billion) would be sufficient to provide treatment for all COPD patients in Russia. At least 7% of the Russian population is affected by this disease. Additionally, there is a growing trend of lung cancer among younger individuals, with lung cancer ranking second as the leading cause of respiratory disease-related deaths in patients aged 35-45.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
![[Breaking] Juul’s Device and 4 Pod Products Officially Authorized by FDA, Reenters the U.S. Regulated Market](https://static.2firsts.com/uploads/20241113/34ffc17feb2b6076367c9e5f413641f2.jpg?x-oss-process=style/origin)
